Upside case
Bull case
$198+59.9%
The bull case requires both strong earnings delivery and the market pricing GILD more generously than it does today.
Analysis OverviewBuyUpdated Jun 18, 2026
Gilead Sciences, Inc. (GILD) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
58
analysts
38 bullish · 1 bearish · 58 covering GILD
Strong Buy
0
Buy
38
Hold
19
Sell
1
Strong Sell
0
Consensus Target
$162
+30.7% vs today
Scenario Range
$95 – $198
Model bear to bull value window
Coverage
58
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $153.7B
GILD price targets
Three scenarios for where GILD stock could go
Current
~$124
Confidence
49 / 100
Updated
Jun 18, 2026
Where we are now
Current · $124
Bear
$95
Base
$150
Bull
$198
Market caseClosest to today
Base case
$150+21.4%
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
$95-23.5%
The bear case assumes sentiment or fundamentals disappoint enough to push GILD down roughly 24% from the current price.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Gilead Sciences, Inc.
GILD · NASDAQHealthcareDrug Manufacturers - GeneralDecember year-end
Gilead Sciences is a biopharmaceutical company focused on developing and commercializing medicines for serious diseases like HIV, viral hepatitis, and cancer. It generates revenue primarily from antiviral drugs — especially HIV treatments like Biktarvy which drive the majority of sales — along with oncology therapies and COVID-19 treatment Veklury. The company's moat lies in its deep expertise in antiviral drug development, a robust HIV franchise with high patient retention, and a pipeline of cell therapy and oncology assets.
Market Cap
$153.7B
Revenue TTM
$29.7B
Net Income TTM
$9.2B
Net Margin
31.0%
GILD Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
92%Exceptional
vs consensus estimates
Avg EPS Surprise
+9.0%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$2.01/$1.96
Revenue
$7.1B/$7.0B
Q4 2025
EPS
$2.47/$2.13
Revenue
$7.8B/$7.4B
Q1 2026
EPS
$1.86/$1.81
Revenue
$7.9B/$7.7B
Q2 2026
EPS
$2.03/$1.91
Revenue
$7.0B/$6.9B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $2.01/$1.96 | +2.6% | $7.1B/$7.0B | +1.4% |
| Q4 2025 | $2.47/$2.13 | +16.0% | $7.8B/$7.4B | +4.3% |
| Q1 2026 | $1.86/$1.81 | +2.8% | $7.9B/$7.7B | +3.1% |
| Q2 2026 | $2.03/$1.91 | +6.3% | $7.0B/$6.9B | +0.7% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$31.8B
+7.1% YoY
FY2
$33.1B
+4.0% YoY
EPS Outlook
FY1
$4.10
-44.2% YoY
FY2
$8.11
+97.9% YoY
Trailing FCF (TTM)$10.2B
FCF Margin: 34.4%
Next Earnings
August 6, 2026
Expected EPS
$-5.88
Expected Revenue
$7.4B
GILD beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
GILD Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $26.0B
Product Mix
Latest annual revenue by segment or product family
Products, Other HIV
79.7%
+5.8% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
UNITED STATES
70.9%
+1.4% YoY
Tap, hover, or focus a slice to inspect segment detail.
Products, Other HIV is the largest disclosed segment at 79.7% of FY 2025 revenue, up 5.8% YoY.
UNITED STATES is the largest reported region at 70.9%, up 1.4% YoY.
GILD Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Cheap versus peers
Fair value est. $163 — implies +31.3% from today's price.
Upside to Fair Value
31.3%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
GILD
18.3x
vs
S&P 500
24.4x
25% discount
vs Healthcare Trailing P/E
GILD
18.3x
vs
Healthcare
22.1x
17% discount
vs GILD 5Y Avg P/E
Today
18.3x
vs
5Y Average
18.6x
In line with benchmark
Forward PE
—
S&P 500
18.8x
—
Healthcare
18.3x
—
5Y Avg
—
—
Trailing PE
18.3x
S&P 500
24.4x
-25%
Healthcare
22.1x
-17%
5Y Avg
18.6x
-2%
PEG Ratio
0.14x
S&P 500
1.66x
-92%
Healthcare
1.59x
-91%
5Y Avg
—
—
EV/EBITDA
11.8x
S&P 500
15.2x
-22%
Healthcare
14.2x
-17%
5Y Avg
15.3x
-23%
Price/FCF
16.2x
S&P 500
20.7x
-21%
Healthcare
18.5x
-12%
5Y Avg
12.5x
+30%
Price/Sales
5.2x
S&P 500
3.1x
+69%
Healthcare
2.6x
+98%
5Y Avg
4.1x
+28%
Dividend Yield
2.58%
S&P 500
1.91%
+35%
Healthcare
1.50%
+72%
5Y Avg
3.41%
-25%
| Metric | GILD | S&P 500 | Healthcare | 5Y Avg GILD |
|---|---|---|---|---|
| Forward PE | — | 18.8x | 18.3x | — |
| Trailing PE | 18.3x | 24.4x-25% | 22.1x-17% | 18.6x |
| PEG Ratio | 0.14x | 1.66x-92% | 1.59x-91% | — |
| EV/EBITDA | 11.8x | 15.2x-22% | 14.2x-17% | 15.3x-23% |
| Price/FCF | 16.2x | 20.7x-21% | 18.5x-12% | 12.5x+30% |
| Price/Sales | 5.2x | 3.1x+69% | 2.6x+98% | 4.1x+28% |
| Dividend Yield | 2.58% | 1.91% | 1.50% | 3.41% |
GILD trades above S&P 500 benchmarks on 1 of 5 measured multiples — appears modestly priced relative to the S&P 500 on most measures.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolGILD Financial Health
Verdict
Exceptional
GILD generates $10.2B in free cash flow at a 34.4% margin — 23.2% ROIC signals a durable competitive advantage · returns 3.8% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$29.7B
Revenue Growth
TTM vs prior year
+3.5%
Gross Margin
Gross profit as a share of revenue
79.4%
Operating Margin
Operating income divided by revenue
38.3%
Net Margin
Net income divided by revenue
31.0%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$7.35
Free Cash Flow (TTM)
Cash generation after capex
$10.2B
FCF Margin
FCF as share of revenue — the primary cash quality signal
34.4%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
23.2%
ROA
Return on assets, trailing twelve months
16.1%
Cash & Equivalents
Liquid assets on the balance sheet
$7.6B
Net Debt
Total debt minus cash
$17.0B
Debt Serviceability
Net debt as a multiple of annual free cash flow
1.7× FCF
~1.7 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
42.3%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
3.8%
Dividend
2.6%
Buyback
1.3%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$1.9B
Dividend / Share
Annualized trailing dividend per share
$3.19
Payout Ratio
Share of earnings distributed as dividends
47.0%
Shares Outstanding
Declining as buybacks retire shares
1.2B
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageGILD Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 17, 2026
High Risk
Weakened EPS Guidance
Gilead Sciences stock has declined due to weakened full-year 2026 EPS guidance and large acquired R&D charges.
Medium
Regulatory Risks
The company faces ongoing regulatory risks that could materially affect business performance and share value.
Medium
Asset Management Risks
Gilead's financial robustness is tempered by asset management risks highlighted in the Q1 2026 report.
Lower
Pipeline Execution
Upcoming PDUFA dates like anito-cel CAR-T in Dec 2026 introduce execution risks for the pipeline.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why GILD Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 17, 2026
Bullish analyst coverage
Multiple bullish theses on Gilead Sciences, Inc. have been published by analysts like Magnus Ofstad and platforms like Disruptive Analytics and Dividend Talks.
Attractive valuation metrics
GILD's trailing P/E of 21.60 and forward P/E of 15.87 suggest the stock may be undervalued relative to earnings potential.
Investor interest growth
The stock is gaining attention across investment platforms including Substack and Reddit's investing communities.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
GILD Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$123.76
52W Range Position
37%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$104.46
+18.5% from the low
52-Week High
$157.29
-21.3% from the high
1 Month
-4.56%
3 Month
-12.41%
YTD
+1.8%
1 Year
+14.6%
3Y CAGR
+16.8%
5Y CAGR
+13.2%
10Y CAGR
+4.1%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
GILD vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 13.5x median
Peer median unavailable
Revenue Growth
+7.1%
vs +6.2% median
+14% above peer median
Net Margin
31.0%
vs 15.0% median
+107% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
GIL GILD Gilead Sciences, Inc. | $153.7B | — | +7.1% | 31.0% | Buy | +30.7% |
ABB ABBV AbbVie Inc. | $383.2B | 15.2x | +8.7% | 6.9% | Buy | +18.6% |
BMY BMY Bristol-Myers Squibb Company | $110.3B | 8.5x | +1.0% | 15.0% | Hold | +15.9% |
AMG AMGN Amgen Inc. | $182.2B | 15.1x | +6.2% | 20.9% | Buy | +3.5% |
BII BIIB Biogen Inc. | $29.0B | 13.5x | +2.8% | 13.9% | Buy | +11.1% |
REG REGN Regeneron Pharmaceuticals, Inc. | $63.4B | 13.1x | +9.0% | 29.6% | Buy | +37.1% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
GILD Dividend and Capital Return
GILD returns 3.8% total yield, led by a 2.58% dividend, raised 11 consecutive years. Buybacks add another 1.3%.
Dividend SustainableFCF Well Covered
Total Shareholder Yield
3.8%
Dividend + buyback return per year
Buyback Yield
1.3%
Dividend Yield
2.58%
Payout Ratio
47.0%
How GILD Splits Its Return
Div 2.58%
Buyback 1.3%
Dividend 2.58%Buybacks 1.3%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$3.19
Growth Streak
Consecutive years of dividend increases
11Y
3Y Div CAGR
2.7%
5Y Div CAGR
3.0%
Ex-Dividend Date
—
Payment Cadence
Quarterly
4 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$1.9B
Estimated Shares Retired
16M
Approx. Share Reduction
1.3%
Shares Outstanding
Current diluted share count from the screening snapshot
1.2B
At 1.3%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $1.64 | — | — | — |
| 2025 | $3.16 | +2.6% | 1.2% | 3.8% |
| 2024 | $3.08 | +2.7% | 1.0% | 4.4% |
| 2023 | $3.00 | +2.7% | 1.0% | 4.7% |
| 2022 | $2.92 | +2.8% | 1.3% | 4.7% |
FAQ
7 questionsGILD Investor Questions
Common questions answered from live analyst data and company financials.
01Is Gilead Sciences, Inc. (GILD) stock a buy or sell in 2026?
Gilead Sciences, Inc. (GILD) is rated Buy by Wall Street analysts as of 2026. Of 58 analysts covering the stock, 38 rate it Buy or Strong Buy, 19 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $162, implying +30.7% from the current price of $124. The bear case scenario is $95 and the bull case is $198.
02What is the GILD stock price target for 2026?
The Wall Street consensus price target for GILD is $162 based on 58 analyst estimates. The high-end target is $180 (+45.4% from today), and the low-end target is $122 (-1.4%). The base case model target is $150.
03Is Gilead Sciences, Inc. (GILD) stock overvalued in 2026?
Forward earnings data for GILD is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
04What are the main risks for Gilead Sciences, Inc. (GILD) stock in 2026?
The primary risks for GILD in 2026 are: (1) Weakened EPS Guidance — Gilead Sciences stock has declined due to weakened full-year 2026 EPS guidance and large acquired R&D charges. (2) Regulatory Risks — The company faces ongoing regulatory risks that could materially affect business performance and share value. (3) Asset Management Risks — Gilead's financial robustness is tempered by asset management risks highlighted in the Q1 2026 report. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Gilead Sciences, Inc.'s revenue and earnings forecast?
Analyst consensus estimates GILD will report consensus revenue of $31.8B (+7.1% year-over-year) and EPS of $4.10 (-44.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $33.1B in revenue.
06When does Gilead Sciences, Inc. (GILD) report its next earnings?
Gilead Sciences, Inc. is expected to report its next earnings on approximately 2026-08-06. Consensus expects EPS of $-5.88 and revenue of $7.4B. Over recent quarters, GILD has beaten EPS estimates 83% of the time.
07How much free cash flow does Gilead Sciences, Inc. generate?
Gilead Sciences, Inc. (GILD) generated $10.2B in free cash flow over the trailing twelve months — a free cash flow margin of 34.4%. GILD returns capital to shareholders through dividends (2.6% yield) and share repurchases ($1.9B TTM).